Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: GNI Group Ltd.

Capitalization 197B 1.23B 1.07B 968M 924M 1.68B 114B 1.74B 11.52B 4.57B 54.45B 4.63B 4.53B P/E ratio 2025
-29.8x
P/E ratio 2026 * 66.1x
Enterprise value 197B 1.23B 1.07B 968M 924M 1.68B 114B 1.74B 11.52B 4.57B 54.45B 4.63B 4.53B EV / Sales 2025
5x
EV / Sales 2026 * 5.91x
Free-Float
91.58%
Yield 2025 *
-
Yield 2026 * -
1 day-9.49%
1 week-11.00%
Current month+1.11%
1 month+29.83%
3 months+28.83%
6 months+25.74%
Current year+32.46%
1 week 3,080
Extreme 3080
3,740
1 month 2,507
Extreme 2507
3,740
Current year 2,265
Extreme 2265
3,740
1 year 1,469
Extreme 1469
4,410
3 years 998
Extreme 998
4,410
5 years 918
Extreme 918
4,410
10 years 473.33
Extreme 473.3333
4,410
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2007
Director of Finance/CFO 46 -
Director of Finance/CFO 65 01/03/2014
Director TitleAgeSince
Director/Board Member 59 01/06/2005
Director/Board Member 67 01/06/2008
Director/Board Member 65 01/03/2013
Change 5d. change 1-year change 3-years change Capi.($)
-9.21%-11.00%+29.25%+208.10% 1.29B
-1.04%-5.85%-10.14%-9.27% 44.08B
-4.55%-2.61%+14.19%+31.94% 33.16B
-1.44%-2.60%+14.63%+45.41% 30.96B
-5.04%-8.72%-12.13%-17.40% 28.8B
-4.54%-4.59%+142.53%+357.95% 19.74B
+0.66%-3.51%+52.36%+115.62% 13.96B
-7.09%-5.44%+36.61%+153.01% 13.56B
-2.41%-6.09%+23.22%-2.78% 12.88B
-3.28%-3.75%+116.52%+113.02% 12.35B
Average -3.82%-2.07%+40.70%+99.56% 21.08B
Weighted average by Cap. -3.07%-4.94%+28.20%+66.13%

Financials

2025 2026 *
Net sales 27.8B 175M 151M 137M 131M 238M 16.12B 246M 1.63B 647M 7.7B 655M 641M 33.25B 209M 181M 164M 156M 284M 19.28B 294M 1.95B 774M 9.21B 784M 767M
Net income 12.96B 81.39M 70.61M 63.84M 60.96M 111M 7.51B 115M 760M 302M 3.59B 305M 299M 2.68B 16.82M 14.59M 13.19M 12.6M 22.91M 1.55B 23.71M 157M 62.34M 742M 63.11M 61.77M
Net Debt - -
Logo GNI Group Ltd.
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Employees
867
Date Price Change Volume
13/03/26 3,205.00 ¥ -9.21% 1,604,600
12/03/26 3,530.00 ¥ -4.21% 1,324,000
11/03/26 3,685.00 ¥ +2.79% 1,524,700
10/03/26 3,585.00 ¥ +7.34% 1,663,100
09/03/26 3,340.00 ¥ -6.96% 2,315,600
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3,530.00JPY
Average target price
4,300.00JPY
Spread / Average Target
+21.81%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW